Astrazeneca (AZN) Tax Provisions (2009 - 2026)

Astrazeneca has reported Tax Provisions for 18 years, with the latest figure at -$291.0 million in Q2 2026.

• On a quarterly basis, Tax Provisions rose 57.14% year-over-year to -$291.0 million in Q2 2026; TTM through Jun 2026 was -$1.8 billion, a 6.68% decrease from a year earlier, with the FY2025 full-year figure at -$2.2 billion, down 31.45% from the prior year.
• Tax Provisions was -$291.0 million for Q2 2026 at Astrazeneca, up from -$833.0 million in the prior quarter.
• The five-year high for Tax Provisions was $720.0 million in Q3 2022, with the low at -$1.0 billion in Q4 2023.
• Average Tax Provisions over 5 years is -$325.2 million, with a median of -$343.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Tax Provisions surged 152.8% in 2022, then tumbled 906.45% in 2023.
• Over 5 years, Tax Provisions stood at $124.0 million in 2022, then sank by 906.45% to -$1.0 billion in 2023, then surged by 83.4% to -$166.0 million in 2024, then jumped by 98.19% to -$3.0 million in 2025, then sank by 9600.0% to -$291.0 million in 2026.
• The last three Tax Provisions figures came in at -$291.0 million (Q2 2026), -$833.0 million (Q1 2026), and -$3.0 million (Q4 2025), per Business Quant data.